C. J. Schyf

发表

Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase

S. Steyn, K. Castagnoli, G. Magnin, 2009, Neurotoxicity Research.

Neuroprotection in mice by NGP1-01 after transient focal brain ischemia

W. Geldenhuys, U. Bickel, T. Abbruscato, 2008, Brain Research.

Haloperidol-Derived Pyridinium Metabolites

S. Pond, C. J. Schyf, N. Castagnoli, 1998 .

Multifunctional neuroprotective–neurorescue drugs for Parkinson’s disease

W. Geldenhuys, M. Youdim, C. J. Schyf, 2007 .

Effects of organophosphorus compounds on ATP production and mitochondrial integrity in cultured cells

B. Jortner, M. Ehrich, C. J. Schyf, 2009, Neurotoxicity Research.

Conformational distribution of the potentially neurotoxic metabolite of haloperidol, HPP+, by NMR spectroscopy, X-ray crystallography and molecular dynamics simulations

J. Wouters, F. Ooms, F. Durant, 1997 .

The use of multi-target drugs in the treatment of neurodegenerative diseases.

C. J. Schyf, 2011 .

Empirical and molecular modeling study of the pyridinium species RHPP+, an abundant and potentially neurotoxic metabolite of haloperidol

J. Wouters, F. Ooms, F. Durant, 2000 .

NGP1-01, a multi-targeted polycyclic cage amine, attenuates brain endothelial cell death in iron overload conditions

W. Geldenhuys, C. J. Schyf, D. D. Allen, 2012, Brain Research.

Chapter 18:Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design

M. Bolognesi, C. Melchiorre, M. Youdim, 2012 .

NGP1-01 is a Brain-permeable Dual Blocker of Neuronal Voltage- and Ligand-operated Calcium Channels

J. Hartmann, C. J. Schyf, T. Thekkumkara, 2006, Neurochemical Research.

Synthesis and biological evaluation of pentacyclo[5.4.0.02,6.03,10.05,9]undecane derivatives as potential therapeutic agents in Parkinson's disease

W. Geldenhuys, J. Bloomquist, S. Malan, 2004 .

7-Nitroindazole

B. Norberg, J. Wouters, F. Ooms, 2000 .

Brain Iron Toxicity: Differential Responses of Astrocytes, Neurons, and Endothelial Cells

W. Geldenhuys, P. Lockman, C. J. Schyf, 2007, Neurochemical Research.

Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations

J. Bloomquist, K. Castagnoli, C. J. Schyf, 2009, Neurotoxicity Research.

Abnormal metal levels in the primary visual pathway of the DBA/2J mouse model of glaucoma

J. Penner‐Hahn, S. Crish, M. Lim, 2014, BioMetals.

NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia

W. Geldenhuys, U. Bickel, T. Abbruscato, 2005, Neuroscience Letters.

Melatonin fails to protect against long-term MPTP-Induced dopamine depletion in mouse striatum

K. Castagnoli, C. J. Schyf, N. Castagnoli, 1999, Neurotoxicity Research.

Multifunctional Neuroprotective Drugs for the Treatment of Alzheimer's Disease

W. Geldenhuys, M. Youdim, C. J. Schyf, 2007 .

Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases

W. Geldenhuys, M. Youdim, C. J. Schyf, 2006 .

Rational drug discovery design approaches for treating Parkinson’s disease

C. J. Schyf, 2015 .

Nicotine Exposure Does not Alter Plasma to Brain Choline Transfer

T. Abbruscato, P. Lockman, C. J. Schyf, 2006, Neurochemical Research.

The emergence of designed multiple ligands for neurodegenerative disorders

W. Geldenhuys, R. T. Carroll, M. Youdim, 2011, Progress in Neurobiology.

Role of Serotonin in Alzheimer’s Disease

W. Geldenhuys, C. J. Schyf, 2011, CNS drugs.

Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease

Neal Castagnoli, M. Schwarzschild, Michael A. Schwarzschild, 2011, Neurotherapeutics.

Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases

C. J. Schyf, 2016 .

Brain Iron Toxicity: Differential Responses of Astrocytes, Neurons, and Endothelial Cells

W. Geldenhuys, P. Lockman, C. J. Schyf, 2007, Neurochemical Research.

Clinical and Neuropathological Abnormalities in Baboons Treated with HPTP, the Tetrahydropyridine Analog of Haloperidol

G. Halliday, S. Pond, H. Cartwright, 1999, Experimental Neurology.

Differential Effect of Nimodipine in Attenuating Iron-Induced Toxicity in Brain- and Blood–Brain Barrier-Associated Cell Types

W. Geldenhuys, C. J. Schyf, D. D. Allen, 2011, Neurochemical Research.

Triquinane scaffolds: Shape and geometry as a function of saturation and bridgehead groups

M. Zeller, W. Geldenhuys, S. Malan, 2013 .

ADME and Ocular Therapeutics: Retina

W. Geldenhuys, D. Inman, Christine Crish, 2013 .

Pharmacology and structure‐activity relationships of bioactive polycyclic cage compounds: A focus on pentacycloundecane derivatives

W. Geldenhuys, C. J. Van der Schyf, J. Bloomquist, 2005, Medicinal research reviews.

The Structure and Ion Channel Activity of 6-Benzylamino-3-hydroxyhexacyclo [6.5.0.03,7.04,12.05,10.09,13] tridecane.

K. Dyason, S. Malan, C. J. Schyf, 2003 .

The midbrain dopaminergic cell groups in the baboon papio ursinus

G. Halliday, S. Pond, H. Cartwright, 1998, Brain Research Bulletin.

Identification of multifunctional small molecule-based reversible monoamine oxidase inhibitors

W. Geldenhuys, M. Lim, C. J. Schyf, 2011 .

Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer ’ s and Parkinson ’ s Diseases

C. J. Schyf, C. J. van der Schyf, 2016 .

Magic bullets or novel multimodal drugs with various CNS targets for Parkinson's disease?

Moussa B. H. Youdim, M. Youdim, C. J. Schyf, 2007, Nature Reviews Drug Discovery.

Abnormal metal levels in the primary visual pathway of the DBA/2J mouse model of glaucoma

J. Penner‐Hahn, S. Crish, M. Lim, 2014, BioMetals.